Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martínez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Türeci Ö, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group.
Muñoz FM, et al. Among authors: czajka h.
N Engl J Med. 2023 Feb 16;388(7):621-634. doi: 10.1056/NEJMoa2211031.
N Engl J Med. 2023.
PMID: 36791162
Free PMC article.
Clinical Trial.
On the basis of preliminary immunogenicity results, a third 3-mug dose (8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (omicron) variant. Immune responses at 1 month after doses 2 and 3 in children 6 mon …
On the basis of preliminary immunogenicity results, a third 3-mug dose (8 weeks after dose 2) was administered starting in January 2022, whi …